Part 2: Targeted Interventions in Meniere’s Disease—Surgical, Medical, and Biological Frontiers
Welcome to Part 2 of our series on the modern clinical paradigm of Meniere’s disease.
In Part 1, we explored the groundbreaking 2025 research by Chari et al., which shattered the 85-year-old “fluid pressure” myth. We learned that endolymphatic hydrops is actually an active, cellular response to endolymphatic sac failure, and that patients present in two distinct endotypes: hypoplastic (MD-hp) and degenerative (MD-dg).
Now that we understand the cellular root of the problem, we must adapt our clinical approach. Here in Part 2, we explore how we transition from outdated “plumbing” protocols to targeted medical, surgical, and biological interventions.
🏥 How Should We Stratify Medical and Surgical Management?
The 2025 Chari et al. framework provides a roadmap for personalized clinical decision-making. Because the underlying pathology differs between endotypes, the treatment response is no longer a “one-size-fits-all” scenario.
🩺 Managing the Hypoplastic Endotype (MD-hp)
These patients often have a high risk of bilateral involvement and smaller anatomical landmarks. Management focuses on vigilant monitoring of the contralateral ear and early hearing preservation strategies. Invasive ablative surgeries (like labyrinthectomy) must be approached with extreme caution, as the risk of losing vestibular function bilaterally is significant.
💊 Managing the Degenerative Endotype (MD-dg)
These patients typically present later with normal or degenerative sac anatomy and often show a higher correlation with vestibular migraine. Medical management should prioritize migraine-preventative medications alongside traditional dietary modifications. Surgically, their more accessible anatomy may make them better candidates for conservative sac decompression, although the updated goal is potentially to stabilize a degenerating environment, not just to drain fluid.
🧬 Can Biologicals Facilitate Inner Ear Homeostasis?
If Meniere’s is truly a cellular response to sac dysfunction, the next generation of treatment must focus on supporting the existing microenvironment at a cellular level. Emerging experimental models are exploring “cell-free” regenerative medicine—specifically, Mesenchymal Stem Cell (MSC)-derived exosomes and secretomes—to promote a more stable inner ear environment.
🧪 The Role of the Secretome
The secretome refers to the array of bioactive proteins, growth factors, and cytokines secreted by stem cells. The goal is to utilize these signals to coordinate fluid and ionic homeostasis within the endolymphatic sac. By coordinating this biological response, we may be able to prevent the native tissue’s repair attempt from devolving into the hyperplastic, dysfunctional remodeling that characterizes late-stage disease.
🔬 The Role of Exosomes
Exosomes are specialized, non-immunogenic vesicles that act as natural delivery vehicles. They can carry critical signaling molecules directly to damaged inner ear tissues, such as the stria vascularis and the endolymphatic sac. By delivering targeted signals that optimize ion transport pathways, experimental biological therapy aims to optimize the local microenvironment and halt cellular degradation.
🧠 Addressing Maladaptive Sensory Strategies
Regardless of the biological or medical intervention, the vestibular professional must address the secondary maladaptive sensory strategies that develop during the active phases of Meniere’s disease.
Fluctuating vestibular signaling creates a profound sensory mismatch, forcing the nervous system to develop maladaptive strategies, specifically a heightened overreliance on visual cues and surface dependence for orientation. Vestibular rehabilitation must prioritize retraining the nervous system to reweight these sensory inputs once the biological microenvironment is optimized. Biological stabilization and targeted sensory retraining work in tandem to maximize functional recovery and reduce
🚀 Summary of the Modern Framework
We are moving from an era of “plumbing” to an era of “signaling.” By combining the precise endotyping described by Chari et al. with the experimental potential of MSC-derived secretomes, we can move toward a future where Meniere’s disease is managed through precision medicine and biological environmental optimization.